Simplification with Boosted Protease Inhibitor-Based ART Versus Maintenance of Conventional ART: Results from a Five-Year Controlled Cohort.

Mateus Swarovsky Helfer, Guilherme Carvalho Serena, Tarsila Vieceli, Eduardo Sprinz

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mateus Swarovsky HelferInfectious Disease Department, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul 90035-903, Brazil.ORCID 0000-0003-3658-4549

Guilherme Carvalho SerenaSchool of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, Brazil.

Tarsila VieceliInfectious Diseases Department, Santa Casa de Porto Alegre, Porto Alegre 90020-090, Brazil.ORCID 0000-0001-6274-1320

Eduardo SprinzInfectious Disease Department, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul 90035-903, Brazil.ORCID 0000-0003-4343-8304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dolutegravir-based antiretroviral therapy (ART) simplification is increasingly common, although some patients cannot take this drug due to intolerance or drug resistance. Boosted-protease inhibitors (bPI) might be an option in this scenario. Nevertheless, long-term outcomes have not been studied yet. A controlled cohort study comparing 5-year outcomes of ART simplification bPI-based regimens (without integrase strand transfer inhibitor-INSTI) versus ART maintenance was conducted in a Brazilian referral center. Viral suppression rates and mortality after 5 years were the primary outcomes of the study. Eighty individuals were included in each group; 47.5% were women, and the mean age was 56 years. The five-year survival rate was 88.8% in the simplified group and 87.5% in the maintenance arm (log-rank = 0.41). Viral suppression rate was 78.8% and 70.0%, respectively (

Indexed as

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveHIV InfectionsHIV Protease InhibitorsAdultAgedBrazilCohort StudiesDolutegravirFemaleHeterocyclic Compounds, 3-RingHIV-1HumansMaleMiddle AgedOxazinesAnti-HIV AgentsDolutegravirHeterocyclic Compounds, 3-RingHIV Protease InhibitorsOxazinesPiperazinesPyridonesAIDSboosted protease inhibitorHIVintegrase inhibitor sparing regimensimplification therapy

Identifiers

PMID40573342

DOI10.3390/v17060751

PMCPMC12197410

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.